PURPOSE: Paclitaxel has a broad spectrum of anti-tumor activity and is useful in the treatment of ovarian, breast, and lung cancer. Paclitaxel is metabolized in the liver by CYP2C8 and CYP3A4 and transported by P-glycoprotein. The dose-limiting toxicities are neuropathy and neutropenia, but the interindividual variability in toxicity and also survival is large. The main purpose of this study was to investigate the impact of genetic variants in CYP2C8 and ABCB1 on toxicity and survival. METHODS: The 182 patients previously treated for ovarian cancer with carboplatin and paclitaxel in either the AGO-OVAR-9 or the NSGO-OC9804 trial in Denmark or Sweden were eligible for this study. Genotyping was carried out on formalin-fixed tissue. The patients' toxicity profiles and survival data were derived from retrospective data. CYP2C8*3, ABCB1 C1236T, G2677T/A, and C3435T were chosen a priori for primary analysis; a host of other variants were entered into an exploratory analysis. RESULTS: Clinical data and tissue were available from a total of 119 patients. Twenty-two single nucleotide polymorphisms (SNPs) in 10 genes were determined. Toxicity registration was available from 710 treatment cycles. In the primary analysis, no statistically significant correlation was found between CYP2C8*3, ABCB1 C1236T, G2677T/A, and C3435T and neutropenia, sensoric neuropathy, and overall survival. CONCLUSION: CYP2C8*3 and the ABCB1 SNPs C1236T, G2677T/A, and C3435T were not statistically significantly correlated to overall survival, sensoric neuropathy, and neutropenia in 119 patients treated for ovarian cancer with paclitaxel/carboplatin.
PURPOSE:Paclitaxel has a broad spectrum of anti-tumor activity and is useful in the treatment of ovarian, breast, and lung cancer. Paclitaxel is metabolized in the liver by CYP2C8 and CYP3A4 and transported by P-glycoprotein. The dose-limiting toxicities are neuropathy and neutropenia, but the interindividual variability in toxicity and also survival is large. The main purpose of this study was to investigate the impact of genetic variants in CYP2C8 and ABCB1 on toxicity and survival. METHODS: The 182 patients previously treated for ovarian cancer with carboplatin and paclitaxel in either the AGO-OVAR-9 or the NSGO-OC9804 trial in Denmark or Sweden were eligible for this study. Genotyping was carried out on formalin-fixed tissue. The patients' toxicity profiles and survival data were derived from retrospective data. CYP2C8*3, ABCB1C1236T, G2677T/A, and C3435T were chosen a priori for primary analysis; a host of other variants were entered into an exploratory analysis. RESULTS: Clinical data and tissue were available from a total of 119 patients. Twenty-two single nucleotide polymorphisms (SNPs) in 10 genes were determined. Toxicity registration was available from 710 treatment cycles. In the primary analysis, no statistically significant correlation was found between CYP2C8*3, ABCB1C1236T, G2677T/A, and C3435T and neutropenia, sensoric neuropathy, and overall survival. CONCLUSION:CYP2C8*3 and the ABCB1 SNPs C1236T, G2677T/A, and C3435T were not statistically significantly correlated to overall survival, sensoric neuropathy, and neutropenia in 119 patients treated for ovarian cancer with paclitaxel/carboplatin.
Authors: T K Bergmann; C Brasch-Andersen; H Gréen; M Mirza; R S Pedersen; F Nielsen; K Skougaard; J Wihl; N Keldsen; P Damkier; L E Friberg; C Peterson; W Vach; M O Karlsson; K Brosen Journal: Pharmacogenomics J Date: 2010-04-06 Impact factor: 3.550
Authors: Tristan M Sissung; Klaus Mross; Seth M Steinberg; Dirk Behringer; William D Figg; Alex Sparreboom; Stephan Mielke Journal: Eur J Cancer Date: 2006-09-06 Impact factor: 9.162
Authors: Sharon E Johnatty; Jonathan Beesley; Jim Paul; Sian Fereday; Amanda B Spurdle; Penelope M Webb; Karen Byth; Sharon Marsh; Howard McLeod; Paul R Harnett; Robert Brown; Anna DeFazio; Georgia Chenevix-Trench Journal: Clin Cancer Res Date: 2008-09-01 Impact factor: 12.531
Authors: D L Hertz; S Roy; A A Motsinger-Reif; A Drobish; L S Clark; H L McLeod; L A Carey; E C Dees Journal: Ann Oncol Date: 2013-02-14 Impact factor: 32.976
Authors: Aparna Chhibber; Deanna L Kroetz; Kelan G Tantisira; Michael McGeachie; Cheng Cheng; Robert Plenge; Eli Stahl; Wolfgang Sadee; Marylyn D Ritchie; Sarah A Pendergrass Journal: Pharmacogenomics Date: 2014-12 Impact factor: 2.533
Authors: Daniel L Hertz; Alison A Motsinger-Reif; Amy Drobish; Stacey J Winham; Howard L McLeod; Lisa A Carey; E Claire Dees Journal: Breast Cancer Res Treat Date: 2012-04-18 Impact factor: 4.872
Authors: R Michael Baldwin; Kouros Owzar; Hitoshi Zembutsu; Aparna Chhibber; Michiaki Kubo; Chen Jiang; Dorothy Watson; Rachel J Eclov; Joel Mefford; Howard L McLeod; Paula N Friedman; Clifford A Hudis; Eric P Winer; Eric M Jorgenson; John S Witte; Lawrence N Shulman; Yusuke Nakamura; Mark J Ratain; Deanna L Kroetz Journal: Clin Cancer Res Date: 2012-07-27 Impact factor: 12.531
Authors: Anne-Joy M de Graan; Laure Elens; Jason A Sprowl; Alex Sparreboom; Lena E Friberg; Bronno van der Holt; Pleun J de Raaf; Peter de Bruijn; Frederike K Engels; Ferry A L M Eskens; Erik A C Wiemer; Jaap Verweij; Ron H J Mathijssen; Ron H N van Schaik Journal: Clin Cancer Res Date: 2013-05-02 Impact factor: 12.531